S. Qin
Peking University
16 Papers
2 Citations
S. Qin is an academic researcher from Peking University. The author has contributed to research in topics: Medicine & Radiation therapy. The author has an hindex of 5, co-authored 6 publications.
Chat about Author
Papers
Prognostic significance of neutrophil-to-lymphocyte ratio in prostate cancer: evidence from 16,266 patients
Xiaobin Gu,Xianshu Gao,Xiaoying Li,Xin Qi,Mingwei Ma,S. Qin,Hao Yu,Shaoqian Sun,Dong Zhou,Wen Wang +9 more
TL;DR: Stratified analysis by PCa type, sample size, ethnicity and NLR cut-off value revealed that NLR showed consistent prognostic value in metastatic castration-resistant prostate cancer patients and predict poor PFS/RFS in Asians, but not in Caucasians.
127
Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3,430 patients
Xiaobin Gu,Shaoqian Sun,Xianshu Gao,Wei Xiong,S. Qin,Xin Qi,Mingwei Ma,Xiaoying Li,Dong Zhou,Wen Wang,Hao Yu +10 more
TL;DR: High PLR especially predicted poor OS in Caucasians but had no association with poor DFS/PFS in Asians, and it was suggested that elevated PLR was associated with poor OS and DFS and PFS in NSCLC.
Prognostic significance of osteopontin expression in gastric cancer: a meta-analysis.
Xiaobin Gu,Xianshu Gao,Mingwei Ma,S. Qin,Xin Qi,Xiaoying Li,Shaoqian Sun,Hao Yu,Wen Wang,Dong Zhou +9 more
TL;DR: OPN overexpression was correlated with poor OS and clinical features reflecting high aggressiveness in patients with GC, and OPN was a promising prognostic biomarker for GC.
BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer
Ming Cui,Xianshu Gao,Xiaobin Gu,Wei Guo,Xiaoying Li,Mingwei Ma,S. Qin,Xin Qi,Mu Xie,Chuan Peng,Yun Bai +10 more
TL;DR: The meta-analysis showed that a BRCA2 mutation predicted poor survival outcomes in patients with prostate cancer, especially in those undergoing treatments with radiotherapy, which could help stratify the high-risk patients and provide clinical strategies for more effective targeted treatments for patients with PCa.
Treatment-related neuroendocrine prostate cancer managed with partial stereotactic ablative radiotherapy (P-SABR) for long-term survival: a case series
Xin Qi,Zhuo Zhang,Xianshu Gao,S. Qin,Yu Bai,Wei Yu,Qun He,Yu Fan,Jian-Hua Zhang,Yuanyuan Jiang,Zhisong He,Hongzhe Li +11 more
TL;DR: Partial stereotactic ablative radiotherapy (P-SABR) as discussed by the authors is a radiotherapy regimen that is used in a SABR boost prior to conventional radiotherapy to enhance the tumor biological effective dose (BED) without increasing the dose to organs at risk.
5